TP53 and non-small cell lung carcinoma: Of note is that patients with metastatic EAp53-LR NSCLC had a median OS longer than 5 years, indicating that the probability of dying (hazard) was reduced by 70% compared with those with metastatic EAp53-HR NSCLC (HR=0.3; 95% CI, 0.14-0.63; p=0.001), and by 48% compared with those without TP53 hotspot mutations (HR=0.52; 95% CI, 0.27-0.99; p=0.049).